EUVIMEDPoznaj EUVIMED
MetaanalyseÜbersichtsarbeitOpen access · CC BY 4.0

The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis

Tasnim Hasan iD, Ellie Medcalf, Bern-Thomas Nyang'wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, Hannah Morgan, Ilaria Motta and 4 more

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad653 ↗

At a glance

Metaanalyse in Clinical Infectious Diseases, 2024. Written by Tasnim Hasan and 15 co-authors. Institution: Faculty of Medicine and Health, University of Sydney, Sydney, Australia. Major MEDLINE topics: Linezolid, Tuberculosis, Tuberculosis, Multidrug-Resistant. Cited 42 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0). Funded by: World Health Organization, World Health Organization..

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Background

Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without a fourth drug, have been shown to be as or more effective than the established longer regimens for the treatment of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB). We aimed to evaluate the safety and tolerability of linezolid in BPaL-containing regimens for the treatment of MDR/RR-TB among recently completed clinical trials.

Methods

A review and meta-analysis was undertaken including published and unpublished data from clinical trials, conducted between 2010 and 2021, that evaluated regimens containing BPaL for the treatment of MDR/RR-TB. Individual patient data were obtained. For each BPaL-containing regimen, we evaluated the frequency and severity of treatment-related adverse events. The risk difference of adverse events for each regimen was calculated, in comparison to patients assigned to receiving the lowest cumulative exposure of linezolid.

Results

Data from 3 clinical trials investigating 8 unique BPaL-containing regimens were included, comprising a total of 591 participants. Adverse events were more frequent in groups randomized to a higher cumulative linezolid dose. Among patients who were randomized to a daily dose of 1200 mg linezolid, 68 of 195 (35%) experienced a grade 3–4 adverse event versus 89 of 396 (22%) patients receiving BPaL-containing regimens containing 600 mg linezolid.

Conclusions

Regimens containing BPaL were relatively well tolerated when they included a daily linezolid dose of 600 mg. These novel regimens promise to improve the tolerability of treatment for MDR/RR-TB.

Subjects

MeSH terms (MEDLINE)

LinezolidTuberculosisTuberculosis, Multidrug-ResistantHumansAntitubercular AgentsDiarylquinolinesNitroimidazolesRandomized Controlled Trials as TopicRifampin

Author keywords

BPaLlinezolidmultidrug-resistant tuberculosissevere adverse events

Substances

Antitubercular AgentsbedaquilineDiarylquinolinesLinezolidNitroimidazolespretomanidRifampin

Authors and institutions

  • Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Public Health Department, Médecins sans Frontières, Amsterdam, The Netherlands.
  • Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • TB Alliance Research and Development, New York City, USA.
  • Manson Unit, Médecins sans Frontières, London, United Kingdom.
  • Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.

ORCID profiles: Tasnim Hasan

Funding

  • World Health Organization
  • World Health Organization.

Cite

APA

Hasan, T., Medcalf, E., Nyang'wa, B. T., Egizi, E., Berry, C., Dodd, M., Foraida, S., Gegia, M., Li, M., Mirzayev, F., Morgan, H., Motta, I., Nguyen, L., Schumacher, S., Schlub, T., & Fox, G. (2024). The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad653

Vancouver

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, Dodd M, et al. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad653

BibTeX
@article{Hasan2024,
  author = {Hasan, Tasnim and Medcalf, Ellie and Nyang'wa, Bern-Thomas and Egizi, Erica and Berry, Catherine and Dodd, Matthew and Foraida, Salah and Gegia, Medea and Li, Mengchun and Mirzayev, Fuad and Morgan, Hannah and Motta, Ilaria and Nguyen, Linh and Schumacher, Samuel and Schlub, Tim and Fox, Greg},
  title = {The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad653}
}
Start for free →